ITGBL1 and colorectal carcinoma: Another study showed that ITGBL1 was associated with the overall survival rate (OSR) and relapse-free survival (RFS) of CRC patients, and subgroup validation demonstrated that a high ITGBL1 expression was correlated with shorter RFS in stage II patients, which suggested that ITGBL1 was a promising candidate biomarker for predicting the relapse of CRC (8).